SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

23 Jan 2025 Evaluate
The revenue zoomed 8.48% to Rs. 23965.70 millions for the quarter ended December 2024 as compared to Rs. 22092.10 millions during the corresponding quarter last year.The Net proft of the company remain more or less same to Rs. 4163.80  millions from Rs. 4627.20 millions ,decline by -10.01%.The company reported a good operating profit of 8107.50 millions compared to 6404.10 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 23965.70 22092.10 8.48 73295.70 65619.60 11.70 92648.09 81271.53 14.00
Other Income 698.20 672.40 3.84 2704.10 1827.90 47.93 2666.38 1627.83 63.80
PBIDT 8107.50 6404.10 26.60 23355.70 18520.60 26.11 25917.44 18601.65 39.33
Interest 1994.70 42.60 4582.39 2076.50 105.40 1870.11 145.70 277.48 -47.49
PBDT 6112.80 6361.50 -3.91 21279.20 18415.20 15.55 25771.74 18324.17 40.64
Depreciation 870.30 896.90 -2.97 2558.50 2352.10 8.78 3176.06 2695.80 17.82
PBT 5242.50 5464.60 -4.06 18720.70 16063.10 16.54 22595.68 15628.37 44.58
TAX 1078.70 837.40 28.82 3690.00 3170.20 16.40 4361.57 3145.79 38.65
Deferred Tax -275.70 16.60 -1760.84 -60.10 317.40 -118.94 195.98 229.43 -14.58
PAT 4163.80 4627.20 -10.01 15030.70 12892.90 16.58 18234.11 12482.58 46.08
Equity 412.57 400.59 2.99 412.57 400.59 2.99 400.59 400.59 0.00
PBIDTM(%) 33.83 28.99 16.70 31.87 28.22 12.90 27.97 22.89 22.22

Mankind Pharma Share Price

2123.20 18.50 (0.88%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×